Author: 

Hua Zhu¹, Jin Ding¹, Xiaoyi Chong², Congcong Ji², Cheng Zhang², Fei Teng³, Yi Gu³, Xueming Qian³, Zhi Yang¹, Lin Shen², Jing Gao⁴

¹Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, China; 

²Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing China; 

³Research, Mabspace Biosciences (Suzhou) Co. Ltd, Suzhou, China; 

⁴National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.

Background: 

Claudin18.2 (CLDN18.2), a member of tight junction protein family, is strictly limited to differentiated epithelial cells of gastric mucosa and is overexpressed in multiple tumor types, such as gastric, esophageal and pancreatic cancers ^[1-2]. We have generated a novel species cross-reactive CLDN18.2 specific antibody, and labeled it with "Next Generation" radionuclide I-124 (¹²⁴|-18B10).

Conclusions:

•The 124|-18B10 antibody has excellent radio-chemical characteristics and stability.

•The antibody probe is shown highly specific to CLDN18.2 in both cell based uptake assay and competitive binding assay.

•Micro-PET images of PDX bearing mice showed that 124|-18B10 was enriched in the lesion of CLDN18.2 positive tumors rather than negative tumors or normal tissues.

•The 18B10, a novel CLDN18.2 specific antibody, has great potential to be further developed as an imaging agent for CLDN18.2 positive cancer patients, indicated by the results of preclinical studies above.